Data from two mid-stage studies show HI-Bio’s investigational therapy felzartamab lowers pathogenic antibody titers in patients with primary membranous nephropathy (PMN).
HI-Bio Advances Rare Kidney Disease Therapy to Late-Stage Studies Read More »
A new open letter from investors Barry Sternlicht, Elliot Cooperstone and Lewis Gold calls on Cano to oust its CEO and sell non-core businesses to focus on profitability.
Cano’s former board members allege conflicts of interest, insider loans Read More »
Transactions were buoyed by a strong first half of the year, with PE deals declining in the second half due to tensions from Russia’s invasion of Ukraine, rising Federal Reserve interest rates and growing inflationary pressures.
Last year was second-best year for healthcare PE deals, Bain finds Read More »
The amount nonprofit hospitals receive in tax breaks over what they spend on charity care in several states could cover all medical debt for residents, according to the Lown Institute.
’Fair share’ deficits at nonprofit hospitals reached $14.2B in 2020 Read More »
BTIG lists 20 companies as competitors to GE HealthCare, including China’s Shenzen Mindray Bio-Medical Electronics and Shanghai United Imaging Healthcare.
GE HealthCare faces ‘competition from all angles’ that could constrain growth: analysts Read More »
Medtech companies are continuing to spin off assets to realign portfolios, creating opportunities for private equity firms to buy businesses and exit existing investments.
Medtech buyouts by private equity in Q4 shed light on deal-making trends in 2023: report Read More »
LyGenesis, Inc. and Imagine Pharma , a biotechnology company focused on the development of its novel polypeptide (IMG-1) across three distinct platforms.
DiaMedica Therapeutics Inc. today announced the appointment of David Wambeke, as Chief Business Officer (CBO).
DiaMedica Therapeutics Appoints David Wambeke as Chief Business Officer Read More »
In an open letter published Monday, more than 480 biopharma industry leaders expressed their support for the FDA after a Texas federal judge ruled to hold the approval of the abortion pill mifepristone.
Biopharma Rallies Behind FDA After Texas Abortion Pill Ruling Read More »
La impulsividad es un rasgo normal de la personalidad y también es habitual que se acentúe durante la adolescencia, pero niveles elevados de esa forma de actuar se relacionan con una predisposición a desarrollar adicciones y, en algunos casos, puede constituir una manifestaci&oa …
Identifican una actividad neuronal asociada a la impulsividad Read More »
